Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 30:12:664109.
doi: 10.3389/fimmu.2021.664109. eCollection 2021.

Dendritic Cells Are the Intriguing Players in the Puzzle of Idiopathic Pulmonary Fibrosis Pathogenesis

Affiliations
Review

Dendritic Cells Are the Intriguing Players in the Puzzle of Idiopathic Pulmonary Fibrosis Pathogenesis

Marialuisa Bocchino et al. Front Immunol. .

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most devastating progressive interstitial lung disease that remains refractory to treatment. Pathogenesis of IPF relies on the aberrant cross-talk between injured alveolar cells and myofibroblasts, which ultimately leads to an aberrant fibrous reaction. The contribution of the immune system to IPF remains not fully explored. Recent evidence suggests that both innate and adaptive immune responses may participate in the fibrotic process. Dendritic cells (DCs) are the most potent professional antigen-presenting cells that bridge innate and adaptive immunity. Also, they exert a crucial role in the immune surveillance of the lung, where they are strategically placed in the airway epithelium and interstitium. Immature DCs accumulate in the IPF lung close to areas of epithelial hyperplasia and fibrosis. Conversely, mature DCs are concentrated in well-organized lymphoid follicles along with T and B cells and bronchoalveolar lavage of IPF patients. We have recently shown that all sub-types of peripheral blood DCs (including conventional and plasmacytoid DCs) are severely depleted in therapy naïve IPF patients. Also, the low frequency of conventional CD1c+ DCs is predictive of a worse prognosis. The purpose of this mini-review is to focus on the main evidence on DC involvement in IPF pathogenesis. Unanswered questions and opportunities for future research ranging from a better understanding of their contribution to diagnosis and prognosis to personalized DC-based therapies will be explored.

Keywords: cancer; dendritic cells; idiopathic pulmonary fibrosis; immunity; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Dendritic cells (DCs) derive from hematopoietic stem cells in the bone marrow. Progenitor cells give rise in the final step to Common Derived Progenitors (CDPs) that differentiate in the blood circulating DC subtypes and in lung tissue DC subsets.
Figure 2
Figure 2
Dendritic cells (DC) are located in the lung interstitium and alveoli, where they act as sentinel cells. Any imbalance of their frequency distribution and functional status may have significant consequences in disease pathogenesis. Emerging evidence suggests that plenty of local factors along with different arrays of chemo-cytokines can modulate DCs maturation in the lung of patients affected by idiopathic pulmonary fibrosis, thus affecting their tolerogenic or immunogenic properties.

References

    1. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global Incidence and Mortality of Idiopathic Pulmonary Fibrosis: A Systematic Review. Eur Respir J (2015) 46(3):795–806. 10.1183/09031936.00185114 - DOI - PubMed
    1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med (2018) 198(5):e44–68. 10.1164/rccm.201807-1255ST - DOI - PubMed
    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. . An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med (2011) 183(6):788–824. 10.1164/rccm.2009-040GL - DOI - PMC - PubMed
    1. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. . Impact of Comorbidities on Mortality in Patients With Idiopathic Pulmonary Fibrosis. PloS One (2016) 11(3):e0151425. 10.1371/journal.pone.0151425 - DOI - PMC - PubMed
    1. Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, et al. . The Added Value of Comorbidities in Predicting Survival in Idiopathic Pulmonary Fibrosis: A Multicentre Observational Study. Eur Respir J (2019) 53(3):1–10. 10.1183/13993003.01587-2018 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources